Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the fourteen brokerages that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $61.92.
CLDX has been the topic of several research reports. HC Wainwright reissued a “buy” rating and set a $64.00 price target on shares of Celldex Therapeutics in a research report on Friday, October 2nd. Cantor Fitzgerald lifted their price objective on shares of Celldex Therapeutics from $61.00 to $72.00 and gave the company an “overweight” rating in a report on Tuesday, September 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Thursday. Wells Fargo & Company upped their target price on shares of Celldex Therapeutics from $48.00 to $72.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Finally, Guggenheim increased their target price on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, July 20th.
View Our Latest Analysis on Celldex Therapeutics
Institutional Trading of Celldex Therapeutics
A number of large investors have recently made changes to their positions in the company. Ellsworth Advisors LLC purchased a new position in Celldex Therapeutics in the third quarter worth approximately $958,000. Mirador Capital Partners LP grew its holdings in Celldex Therapeutics by 6.7% during the 3rd quarter. Mirador Capital Partners LP now owns 193,267 shares of the biopharmaceutical company’s stock worth $6,264,000 after acquiring an additional 12,213 shares in the last quarter. Engineers Gate Manager LP purchased a new stake in shares of Celldex Therapeutics in the 2nd quarter valued at approximately $1,259,000. Arizona State Retirement System increased its position in shares of Celldex Therapeutics by 13.0% in the 2nd quarter. Arizona State Retirement System now owns 18,565 shares of the biopharmaceutical company’s stock valued at $691,000 after purchasing an additional 2,139 shares during the last quarter. Finally, Nykredit A S purchased a new stake in shares of Celldex Therapeutics in the 2nd quarter valued at approximately $67,000.
Celldex Therapeutics Trading Up 4.0%
CLDX stock opened at $28.93 on Friday. The company has a market capitalization of $2.27 billion, a PE ratio of -6.65 and a beta of 0.90. Celldex Therapeutics has a 12-month low of $22.10 and a 12-month high of $45.14. The business’s fifty day moving average price is $36.84 and its 200 day moving average price is $34.86.
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.12. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.73 million. Research analysts predict that Celldex Therapeutics will post -4.17 EPS for the current fiscal year.
About Celldex Therapeutics
Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for diseases with significant unmet medical needs. The company’s research programs target mast cell–mediated disorders, inflammatory diseases, and cancer, using engineered antibodies designed to modulate specific immune-system pathways.
Celldex’s lead product candidate is barzolvolimab, an investigational monoclonal antibody that targets the KIT receptor on mast cells.
Featured Stories
- Five stocks we like better than Celldex Therapeutics
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
